Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Antiviral Therapy in Infants With HBV Infection
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06503796
- Locations
- 🇨🇳
the Fifth Medical Center of PLA, Beijing, China
Lamivudine for Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Thomas Marron
- Target Recruit Count
- 24
- Registration Number
- NCT06494579
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
STARLITE for Unresectable High-Grade Gliomas
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 24
- Registration Number
- NCT06428045
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 412
- Registration Number
- NCT05979311
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Duke University
- Target Recruit Count
- 200
- Registration Number
- NCT04862975
- Locations
- 🇿🇦
Botswana-UPenn Partnership, Botswana, Gaborone, South Africa
🇿🇦Old Naledi Clinic, Botswana, Gaborone, South Africa
🇿🇦Mogoditshane Clinic KDC, Botswana, Gaborone, South Africa
Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 28
- Registration Number
- NCT04696575
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 12
- Registration Number
- NCT04552795
- Locations
- 🇺🇸
Sam and Ann Barshop Institute for Longevity & Aging Studies, San Antonio, Texas, United States
🇺🇸Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio, Texas, United States
🇺🇸University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- HeNan Sincere Biotech Co., Ltd
- Target Recruit Count
- 720
- Registration Number
- NCT04303598
- Locations
- 🇨🇳
Beijing DiTan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China
🇨🇳Chongqing Public Health Medical Center, Chongqing, Chongqing, China
ANRS 12372 MODERATO Study
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 480
- Registration Number
- NCT04022967
- Locations
- 🇨🇮
Service des Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville, Abidjan, Côte D'Ivoire
🇧🇫Service de médecine interne, CHU Yalgado Ouédraogo, Ouagadougou, Burkina Faso
🇧🇫Hôpital de jour, Service des maladies infectieuses, CHU Sourô Sanou, Bobo-Dioulasso, Burkina Faso
Nucleosides And Darunavir/Dolutegravir In Africa
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 465
- Registration Number
- NCT03988452
- Locations
- 🇺🇬
Infectious Diseases Institute, Kampala, Uganda
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.